Brighton Jones LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 259.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 18,130 shares of the company’s stock after purchasing an additional 13,092 shares during the quarter. Johnson & Johnson accounts for 0.5% of Brighton Jones LLC’s holdings, making the stock its 20th biggest holding. Brighton Jones LLC’s holdings in Johnson & Johnson were worth $2,258,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lau Associates LLC increased its position in shares of Johnson & Johnson by 12.8% during the 1st quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after purchasing an additional 5,335 shares during the last quarter. Burke & Herbert Bank & Trust Co. increased its position in shares of Johnson & Johnson by 2.6% during the 1st quarter. Burke & Herbert Bank & Trust Co. now owns 47,330 shares of the company’s stock valued at $5,895,000 after purchasing an additional 1,218 shares during the last quarter. Paradigm Financial Advisors LLC increased its position in shares of Johnson & Johnson by 17.1% during the 1st quarter. Paradigm Financial Advisors LLC now owns 2,640 shares of the company’s stock valued at $328,000 after purchasing an additional 386 shares during the last quarter. Trexquant Investment LP bought a new position in shares of Johnson & Johnson during the 1st quarter valued at approximately $1,731,000. Finally, Peachtree Investment Advisors Inc. increased its position in shares of Johnson & Johnson by 0.7% during the 1st quarter. Peachtree Investment Advisors Inc. now owns 22,138 shares of the company’s stock valued at $2,757,000 after purchasing an additional 160 shares during the last quarter. 66.00% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts have recently weighed in on JNJ shares. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Cowen and Company reissued a “buy” rating and set a $143.00 target price (up previously from $138.00) on shares of Johnson & Johnson in a research report on Friday, May 19th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $132.33 target price on the stock in a research report on Thursday, May 18th. BMO Capital Markets reissued a “buy” rating and set a $132.00 target price on shares of Johnson & Johnson in a research report on Friday, June 2nd. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $128.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 15th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $134.60.

In other news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.51% during midday trading on Wednesday, hitting $131.96. The company’s stock had a trading volume of 1,814,635 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm has a market cap of $354.18 billion, a price-to-earnings ratio of 22.33 and a beta of 0.79. The firm has a 50-day moving average of $132.42 and a 200 day moving average of $128.96.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.74 earnings per share. On average, equities research analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.76%.

WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/13/brighton-jones-llc-has-2-26-million-stake-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.